Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Credit agrmnt [a]
Acq. announced
Director departure
CC transcript
Actavis, Inc. (ACT) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/08/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/29/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Actavis Net Revenue Increases 57% to $2.01 Billion in Third Quarter 2013; Non-GAAP EPS Increases 55% to $2.09"
10/22/2013 8-K Regulation FD Disclosure
10/02/2013 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Amended and Restated Articles of Incorporation of Actavis, Inc",
"Third Amended and Restated Bylaws of Actavis, Inc"
10/02/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Actavis and Warner Chilcott Receive Approval from Irish High Court For Pending Warner Chilcott Acquisition"
09/11/2013 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Actavis and Warner Chilcott Shareholders Approve Proposals Related to Actavis' Proposed Acquisition of Warner Chilcott"
08/29/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Actavis' Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms",
"Actavis' Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms"
08/02/2013 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PricewaterhouseCoopers Report",
"BofA Merrill Lynch & Greenhill Report"
08/02/2013 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Term Loan Amendment Agreement, by and among Actavis, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto",
"Revolver Loan Amendment Agreement, by and among Actavis, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto",
"Amended and Restated Actavis Term Loan Credit Facility, by and among Actavis WC Holding S.à r.l., Actavis, Inc., Actavis plc, the lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, to be dated as of the Closing Date",
"Amended and Restated Actavis Revolving Credit Facility, by and among Actavis WC Holding S.à r.l., Actavis, Inc., Actavis plc, the lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, to be dated as of the Closing Date",
"Warner Chilcott Term Loan Credit Facility, by and among Actavis plc, Warner Chilcott Corporation, WC Luxco S.à r.l, Warner Chilcott Company LLC, Warner Chilcott Finance LLC, the lenders from time to time party thereto and Bank of America, N.A., as Administrative Agent, to be"
05/02/2013 8-K Form 8-K - Current report
02/19/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion"
01/25/2013 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "Stock Purchase Agreement, by and among Actavis, Inc. (formerly Watson Pharmaceuticals, Inc.), a Nevada corporation, Watson Pharma Actavis S.a.r.l. and each of the shareholders of Uteron Pharma SA, a company incorporated in Belgium",
"Watson Acquires Uteron Pharma SA"
01/25/2013 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Actavis Details Strategy for Continued Long-Term Growth"
01/08/2013 8-K Cost Associated with Exit or Disposal Activities
11/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Key Employee Agreement by and between Paul M. Bisaro and Watson Pharmaceuticals, Inc"
11/02/2012 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Departure of Directors or Cer...
Docs: "Deed of Modification and Withdrawal from Escrow Accounts, to the Sale and Purchase Agreement dated April 25, 2012, by and among Nitrogen DS Limited, Landsbanki Islands hf., ALMC Eignarhaldsfélag ehf., ALMC hf., Argon Management S.à r.l., the Managers party thereto, Deutsche Bank AG, London Branch, Actavis Acquisition Debt S.à r.l., Watson Pharma S.à r.l. and Watson Pharmaceuticals, Inc",
"Watson Completes Actavis Acquisition",
"Watson Announces New Name - Actavis - for Global Operations",
"Watson Announces Global Generics Management Team"
11/01/2012 8-K Form 8-K - Current report
09/27/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Consent of KPMG ehf., independent auditors"
07/26/2012 8-K Form 8-K - Current report
06/26/2012 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Term Loan Credit Agreement by and among Watson Pharmaceuticals, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto"
05/23/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 1 to Credit Agreement and Joinder Agreement by and among Watson Pharmaceuticals, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto"
05/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/30/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "- Sigurdur Oli Olafsson Named President, Global Generics - G. Frederick Wilkinson Named President, Global Brands - Robert A. Stewart Named President, Global Operations - David A. Buchen Named Chief Legal Officer - Global - R. Todd Joyce Named Chief Financial Officer - Global - Charles M. Mayr Named Chief Communications Officer - Global - Patrick J. Eagan Named Senior Vice President Human Resources - Global"
04/30/2012 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Watson First Quarter 2012 Non-GAAP EPS Increases 84% to $1.64; Net Revenue Increases 74% to $1.5 Billion"
04/25/2012 8-K Investor presentation
Docs: "Watson to Acquire Actavis Group for EUR4.25 Billion",
"Investor Presentation"
02/14/2012 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; - Full Year 2011 Non-GAAP EPS Increases 39% To $4.77 ; GAAP EPS $2.06 - - Fourth Quarter 2011 Net Revenue $1.54 Billion - - Fourth Quarter 2011 Non-GAAP EPS $1.77; GAAP EPS $0.75 -",
"Table entitled “Watson Pharmaceuticals, Inc. Non-GAAP Reconciliation Table - Fourth Quarter Ended December 31, 2011.”",
"Table entitled “Watson Pharmaceuticals, Inc. Non-GAAP Reconciliation Table - Twelve Months Ended December 31, 2011.”"
01/26/2012 8-K Form 8-K - Current report
01/24/2012 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77 - Preliminary Net Revenues Climb Approximately 28% to Approximately $4.57 Billion - - Company Discusses Strategic Rationale for Ascent Acquisition and Advisory Committee Action Related to Progesterone Gel 8% - - Provides 2012-2013 Forecast -",
"Watson Acquires Ascent Pharmahealth for AU$375 Million"
01/19/2012 8-K Form 8-K - Current report
12/19/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AMGEN AND WATSON ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE ONCOLOGY BIOSIMILARS"
11/01/2011 8-K Form 8-K - Current report
09/19/2011 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Credit Agreement by and among Watson Pharmaceuticals, Inc., Bank of America, N.A., as Administrative Agent, Wells Fargo Bank, N.A., as Syndication Agent, and a syndicate of Lenders"
07/26/2011 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01 - 24% Increase in Net Revenue and Non-GAAP Net Income - - 17% Increase in Adjusted EBITDA - - Company Increases Full Year 2011 Revenue and Earnings Forecast -",
"Table entitled “Watson Pharmaceuticals, Inc. Non-GAAP Reconciliation Table — Second Quarter Ended June 30, 2011.”"
05/27/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy